Why Cryoport, Inc.’s (CYRX) Stock Is Up 6.03%
As of Wednesday, August 19, Cryoport, Inc.’s CYRX share price has surged by 6.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Commentary & Analysis
Why Cryoport, Inc.’s (CYRX) Stock Is Up 5.76%
As of Wednesday, June 24, Cryoport, Inc.’s CYRX share price has surged by 5.76%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Cryoport, Inc.’s (CYRX) Stock Is Up 5.53%
As of Wednesday, May 20, Cryoport, Inc.’s CYRX share price has surged by 5.53%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cryoport, Inc.’s (CYRX) Stock Is Up 5.02%
As of Friday, May 08, Cryoport, Inc.’s CYRX share price has surged by 5.02%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Cryoport, Inc.’s (CYRX) Stock Is Up 18.51%
As of Tuesday, May 05, Cryoport, Inc.’s CYRX share price has surged by 18.51%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CYRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $826.1 | $3,697.4 | 43% |
|
| Shares Out (Mil) | 50.4 | 98.2 | 48% |
|
| Institutional Ownership | 96.1% | 89.0% | 69% |
|
| Float (Mil) | 45.9 | 69.9 | 45% |
|
| Beta | 1.89 | 1.19 | 90% |
|
| Avg Daily Volume (000s) | 453 | 803 | 58% |
|
| Price Change (52-week) |
88.8% | 86.1% | 91% |
|
| Growth | CYRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.5% | 7.7% | 78% |
|
| Net Income (5yr) | 34.5% | (12.1%) | 88% |
|
| EPS (5yr) | 22.2% | 2.1% | 72 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 76.6% | (14.9%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.173) | ($0.770) | ($0.663) | |
| Month Ago EPS | ($0.173) | ($0.770) | ($0.663) | |
| # Rev Up | 0 | 2 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.163) | ($0.733) | ($0.620) | |
| Year/Year Chg | (14.8%) | (8.1%) | (42.7%) | |
| Financials | CYRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $187 | $810 | 31% |
|
| Net Income (TTM) (Mil) | ($37) | ($31) | 19% |
|
| EPS (TTM) | ($0.906) | ($0.300) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | $8 | $56 | 37% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $42 | $252 | 38% |
|
| Enterprise Value (Q1) (Mil) | $647 | $3,264 | 36% |
|
| Valuation | CYRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.86 | 3.58 | 48% |
|
| P/E | na | 40.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.8 | na |
|
| Ratios | CYRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.1% | 47.6% | 59% |
|
| Net Margin | (20.1%) | (4.6%) | 17% |
|
| ROA | (4.9%) | (4.7%) | 30% |
|
| ROE | (8.1%) | (7.7%) | 29% |
|
| Liabilities to Assets | 35.1% | 41.1% | 26% |
|
| F-Score | 5 | 5 | 50% |
|
Cryoport, Inc. did not pass any screens on 9/15/2026.
